|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MORC3 |
Gene summary for MORC3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MORC3 | Gene ID | 23515 |
| Gene name | MORC family CW-type zinc finger 3 | |
| Gene Alias | NXP2 | |
| Cytomap | 21q22.12 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | B4DHJ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23515 | MORC3 | CCI_1 | Human | Cervix | CC | 2.11e-02 | 5.88e-01 | 0.528 |
| 23515 | MORC3 | CCI_2 | Human | Cervix | CC | 3.92e-07 | 8.43e-01 | 0.5249 |
| 23515 | MORC3 | CCI_3 | Human | Cervix | CC | 3.79e-03 | 5.71e-01 | 0.516 |
| 23515 | MORC3 | LZE4T | Human | Esophagus | ESCC | 3.05e-13 | 3.86e-01 | 0.0811 |
| 23515 | MORC3 | LZE7T | Human | Esophagus | ESCC | 1.93e-04 | 4.94e-01 | 0.0667 |
| 23515 | MORC3 | LZE8T | Human | Esophagus | ESCC | 3.54e-02 | 9.43e-02 | 0.067 |
| 23515 | MORC3 | LZE20T | Human | Esophagus | ESCC | 1.12e-08 | 1.20e-01 | 0.0662 |
| 23515 | MORC3 | LZE24T | Human | Esophagus | ESCC | 2.87e-17 | 6.76e-01 | 0.0596 |
| 23515 | MORC3 | LZE21T | Human | Esophagus | ESCC | 1.10e-05 | 2.58e-01 | 0.0655 |
| 23515 | MORC3 | P1T-E | Human | Esophagus | ESCC | 1.32e-03 | 3.49e-01 | 0.0875 |
| 23515 | MORC3 | P2T-E | Human | Esophagus | ESCC | 5.95e-19 | 2.95e-01 | 0.1177 |
| 23515 | MORC3 | P4T-E | Human | Esophagus | ESCC | 4.98e-21 | 5.85e-01 | 0.1323 |
| 23515 | MORC3 | P5T-E | Human | Esophagus | ESCC | 4.29e-24 | 5.46e-01 | 0.1327 |
| 23515 | MORC3 | P8T-E | Human | Esophagus | ESCC | 5.15e-17 | 2.71e-01 | 0.0889 |
| 23515 | MORC3 | P9T-E | Human | Esophagus | ESCC | 1.01e-08 | 1.52e-01 | 0.1131 |
| 23515 | MORC3 | P10T-E | Human | Esophagus | ESCC | 2.49e-23 | 3.59e-01 | 0.116 |
| 23515 | MORC3 | P11T-E | Human | Esophagus | ESCC | 2.85e-06 | 5.86e-01 | 0.1426 |
| 23515 | MORC3 | P12T-E | Human | Esophagus | ESCC | 7.04e-19 | 3.77e-01 | 0.1122 |
| 23515 | MORC3 | P15T-E | Human | Esophagus | ESCC | 2.18e-11 | 3.12e-01 | 0.1149 |
| 23515 | MORC3 | P16T-E | Human | Esophagus | ESCC | 1.19e-14 | 1.97e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
| GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
| GO:003164710 | Cervix | CC | regulation of protein stability | 63/2311 | 298/18723 | 1.14e-05 | 2.45e-04 | 63 |
| GO:00075695 | Cervix | CC | cell aging | 34/2311 | 132/18723 | 1.92e-05 | 3.53e-04 | 34 |
| GO:00325077 | Cervix | CC | maintenance of protein location in cell | 21/2311 | 65/18723 | 2.03e-05 | 3.71e-04 | 21 |
| GO:004518510 | Cervix | CC | maintenance of protein location | 26/2311 | 94/18723 | 4.85e-05 | 7.34e-04 | 26 |
| GO:005082110 | Cervix | CC | protein stabilization | 43/2311 | 191/18723 | 5.90e-05 | 8.54e-04 | 43 |
| GO:00181057 | Cervix | CC | peptidyl-serine phosphorylation | 63/2311 | 315/18723 | 6.65e-05 | 9.47e-04 | 63 |
| GO:00182096 | Cervix | CC | peptidyl-serine modification | 66/2311 | 338/18723 | 9.58e-05 | 1.25e-03 | 66 |
| GO:00725955 | Cervix | CC | maintenance of protein localization in organelle | 14/2311 | 42/18723 | 3.32e-04 | 3.49e-03 | 14 |
| GO:00097915 | Cervix | CC | post-embryonic development | 20/2311 | 80/18723 | 1.40e-03 | 1.10e-02 | 20 |
| GO:00514571 | Cervix | CC | maintenance of protein location in nucleus | 8/2311 | 23/18723 | 4.70e-03 | 2.82e-02 | 8 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
| GO:0045185111 | Esophagus | ESCC | maintenance of protein location | 71/8552 | 94/18723 | 3.41e-09 | 7.24e-08 | 71 |
| GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
| GO:0032507110 | Esophagus | ESCC | maintenance of protein location in cell | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MORC3 | SNV | Missense_Mutation | c.1610A>C | p.Glu537Ala | p.E537A | Q14149 | protein_coding | tolerated(0.33) | benign(0.001) | TCGA-A2-A0EU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MORC3 | SNV | Missense_Mutation | novel | c.1886N>T | p.Ser629Leu | p.S629L | Q14149 | protein_coding | tolerated(0.21) | benign(0.022) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| MORC3 | SNV | Missense_Mutation | novel | c.2506N>A | p.Glu836Lys | p.E836K | Q14149 | protein_coding | tolerated(0.36) | benign(0.355) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| MORC3 | SNV | Missense_Mutation | novel | c.902N>C | p.Ile301Thr | p.I301T | Q14149 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MORC3 | SNV | Missense_Mutation | novel | c.2427N>A | p.Met809Ile | p.M809I | Q14149 | protein_coding | tolerated(0.45) | benign(0.009) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MORC3 | SNV | Missense_Mutation | c.1155N>C | p.Met385Ile | p.M385I | Q14149 | protein_coding | tolerated(0.46) | benign(0.039) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MORC3 | SNV | Missense_Mutation | c.1288C>T | p.Pro430Ser | p.P430S | Q14149 | protein_coding | deleterious(0.03) | possibly_damaging(0.669) | TCGA-MY-A5BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MORC3 | SNV | Missense_Mutation | novel | c.2187N>C | p.Gln729His | p.Q729H | Q14149 | protein_coding | tolerated(0.05) | benign(0.26) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| MORC3 | SNV | Missense_Mutation | rs780018142 | c.1214G>A | p.Arg405His | p.R405H | Q14149 | protein_coding | deleterious(0.02) | benign(0.02) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MORC3 | SNV | Missense_Mutation | c.568G>T | p.Gly190Cys | p.G190C | Q14149 | protein_coding | deleterious(0) | possibly_damaging(0.779) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |